Health
Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLC – MedPage Today
More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab.
Neoadjuvant combination immunotherapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) produced a significant clinical benefit for patients with operable stage I-III non-small cell lung cancer (NSCLC), researchers reported.
The phase II NEOSTAR study randomly assigned 44 patients with operable NSCLC to neoadjuvant nivolumab with or without ipilimumab followed by surgery. Among those, 38% of patients that received the combination achieved major pathological response (MPR) — defined as 10% or less…
-
Noosa News23 hours agoFatal Traffic Crash, South Bingera
-
Noosa News14 hours agoTallest tower outside CBD approved for construction at 205 metres
-
Noosa News19 hours agoTrucking company penalised for refusing to pay unfairly sacked worker
-
General21 hours agoVacherot becomes lowest-ranked ATP Masters winner after defeating his cousin Rinderknech in Shanghai